A structurally leveraged (3.4× net-debt/EBITDA) low-growth name in a rising-rate / private-label squeeze
One-line thesis. McCormick is a genuinely high-quality, wide-moat spice franchise (38% gross margin, 26% ROE, a 39-year dividend-raise streak) — but it grows only mid-single-digits, carries 3.4× net-debt/EBITDA, and the stock is in a real down-trend (−31% over 12 months), so at ~$53 it is close to fairly valued rather than cheap. Watch, not Buy — wait for either a lower price or a growth re-acceleration.
◆ Synthos call — HoldMKC is a solid business largely reflected at ~$55 — fine to keep, no reason to chase; it gets interesting again below ~$47.
Downside Risk (lower = safer)
5/10 · Moderate
Low beta (0.64) & defensive demand, but 3.4× net-debt/EBITDA and a live downtrend (−31% 12-mo).
Growth Quality
4/10 · Moderate
Only ~5% forward revenue / ~9% EPS CAGR; solid 38% gross margin & 26% ROE, but slow.
Exponential Potential
2/10 · Low
Mature, decelerating spice compounder near its TAM ceiling — no exponential path.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 4%/yrTo justify today’s $53, earnings would have to compound roughly 4% a year for 10 years (9% discount rate). Analysts forecast ~8%/yr, so the market is pricing in LESS than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
McCormick is the company behind the spices and seasonings in your kitchen — the little red-capped McCormick jars, plus French's mustard, Frank's RedHot, Cholula, Old Bay, and Zatarain's. Half the business sells to shoppers in grocery stores; the other half sells flavors and seasonings in bulk to big food companies and restaurants. It's a slow, steady, recession-resistant business — people keep buying spices whether the economy is good or bad.
Is the stock cheap or expensive? Roughly fair — neither a bargain nor overpriced. You're paying about 16–18× next year's earnings for a company growing profits only about 9% a year, and it pays a solid 3.5% dividend. The stock has actually fallen about 31% over the past year, so it's much cheaper than it was — but it's still drifting down, not turning up.
Our verdict is Watch: a fine company, but there's no urgency to buy today.
Here's what our three scores mean in everyday terms:
Downside Risk 5/10 (middle of the road). The business is stable and the stock is calm (it doesn't swing wildly), but the company carries a fair amount of debt and the price trend is still heading down.
Growth Quality 4/10 (below average). It's profitable and dependable, but it grows slowly — think a steady walk, not a run.
Exponential Potential 2/10 (low). This is a mature, century-old business. It won't multiply your money quickly; it's a bond-like, dividend-paying holding.
The one big worry: McCormick owes about 3.4 years of profits in debt, and cheaper store-brand ("private label") spices can eat into its sales when shoppers pinch pennies. Slow growth plus meaningful debt is why we say wait.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = MKC · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$53.45
Market cap$14B
P/E trailing2×
P/E FY26E / FY27E17× / 16×
EV / Sales2.6×
EV / EBITDA13.8×
Gross margin38.6%
Net margin22.0%
Dividend yield3.48%
Beta0.641
52-wk range$46 – $77
RSI(14)64
50 / 200-DMA$48 / $60
12-mo return+-31% (SPY +21%)
Street target$61 ($52–$72)
Analyst grades11 Buy · 17 Hold · 2 Sell
FMP ratingA
Next earnings2026-08-05
What the experts actually said 0 traceable claims on MKC · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
McCormick & Company (NYSE: MKC), founded 1889 and headquartered in Hunt Valley, Maryland, is the global leader in spices, seasonings, condiments, and flavors. Fiscal year ends November 30. The business runs in two segments:
Consumer (branded, sold to retailers/e-commerce): McCormick, French's, Frank's RedHot, Cholula, Lawry's, Old Bay, Zatarain's, Gourmet Garden; plus Ducros/Schwartz/Kamis in EMEA and DaQiao in China.
Flavor Solutions (B2B, sold to food manufacturers and foodservice): custom seasoning blends, coating systems, and technical flavor formulations for large clients.
Revenue mix (FY2025, from filings):
By segment: Consumer $3.95B (58%) · Flavor Solutions $2.89B (42%). Consumer carries the higher margin; Flavor Solutions is stickier (embedded in customers' recipes) but grows with its clients.
By geography: Americas $4.87B (71%) · EMEA $1.27B (19%) · Asia-Pacific $0.70B (10%). Heavily US/Americas-weighted; China (inside APAC) has been a persistent soft spot.
The strategic story is unglamorous and durable: pricing power on branded spices, a slow global volume grind, cost/supply-chain productivity ("CCI" savings program), and steady deleveraging after the 2020–21 Cholula/FONA acquisitions.
2. The expert thesis (no coverage — stated plainly)
There is no expert coverage of MKC in the Synthos knowledge base: total_claims = 0, zero net-bullish voices, zero traceable claim_ids. None of the panel voices Synthos tracks have made a durable, distilled call on McCormick.
That means this note carries no conviction-track signal — the verdict below is entirely fundamentals- and quant-driven (financial statements, analyst estimates, valuation, and technicals from FMP). We will not manufacture a thesis we cannot trace. If and when a tracked voice covers MKC, this section and the conviction rating will be updated.
For external context only (not a Synthos conviction input): the sell-side is split-to-cautious — 11 Buy, 17 Hold, 2 Sell (consensus Hold), price-target consensus $61.40. FMP's letter model rates the balance sheet weak (debt-to-equity score 2/5) but returns strong (ROE/ROA 5/5), netting an "A" headline that we treat skeptically given the leverage.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Beta 0.64 and staple demand cushion the downside, and forward valuation (16–18×) is reasonable — but net-debt/EBITDA 3.4× is elevated, and the stock is in a live downtrend (−31% 12-mo, below the 200-DMA, −49% max drawdown from peak).
Growth Quality
4 · Below-average
38% gross margin, 26% ROE, ~$740M FCF and a 39-yr dividend-raise streak are high-quality — but forward revenue CAGR is only ~5% and EPS ~9%, and organic volume growth has been anemic. Quality is real; the growth is slow.
Exponential Potential
2 · Low
A 137-year-old spice company at ~$14B with a mature TAM and decelerating growth. No accelerating second derivative, no multibagger path. It compounds like a bond-plus, not an exponential.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Volume growth re-accelerates (Frank's/Cholula/hot-sauce mix + Flavor Solutions win-back), gross margin pushes toward 40%, deleveraging continues. FY27E EPS beats to ~$3.55 (vs $3.30 cons); multiple re-rates to a staple-premium ~19×.
~$68 (+27%)
Base(our anchor)
Estimates roughly hit — FY27E EPS ~$3.30; a dependable but slow ~mid-single-digit compounder with 3.4× leverage earns a ~16–17× multiple.
~$55 (+3%)
Bear
Private-label share gains, US volume stays soft, China stays weak, and higher-for-longer rates keep pressuring the leveraged balance sheet. FY27E EPS misses to ~$3.05; multiple de-rates to ~13×.
~$40 (−25%)
Synthos fair value = the base case, ~$55 (+3%), with the full $40–$68 span as the honest range. Our anchor sits below the Street's $61.40 consensus — we are less willing to pay up for ~5% top-line growth carrying 3.4× leverage in a downtrend. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). MKC is a mature compounder with essentially no exponential profile:
Forward growth: revenue CAGR FY25→FY30E ~5.3% ($6.84B → $8.84B); EPS CAGR ~9.5% ($2.94 → $4.63E) — the gap is buybacks, margin, and deleveraging, not volume.
Acceleration (the 2nd derivative) is flat-to-negative: revenue was $6.32B (FY22) → $6.66B (FY23) → $6.72B (FY24) → $6.84B (FY25) — low-single-digit and not speeding up. This is the opposite of the accelerating profile Synthos rewards.
Room to run: the global spice/flavor category is large but McCormick is already the #1 branded player — it is near its share ceiling in its core markets, so incremental growth is grind-it-out, not blue-sky TAM capture. Emerging-markets and Flavor Solutions are the only real expansion legs, and both are modest.
Reinvestment runway: capex is a light ~3% of revenue; the company returns cash via dividends (~$483M/yr) rather than reinvesting for hyper-growth — the correct choice for a mature staple, but it caps upside.
Exponential Potential: Low (2/10). Own MKC — if at all — for its dividend and defensiveness, never for exponential upside. A small, accelerating flavor-tech name would score 8–9 here; a $14B, 5%-growth incumbent scores 2.
Revenue: FY25 $6.84B, +1.7% (FY24 $6.72B, +0.9% on FY23 $6.66B). Steady but slow; the multi-year CAGR is low-single-digit.
Quarterly trajectory: Q1 FY26 $1.874B → Q2 FY26 $1.937B (+16.7% YoY vs Q2 FY25 $1.660B) — a healthier recent print, and Q2 FY26 EPS $0.56 continuing (the headline $0.56 GAAP; note Q1 FY26 GAAP EPS of $3.78 was inflated by an $886M one-time discontinued-operations gain — strip it out for the true run-rate).
Margins: gross 38.6% TTM (stable, a spice-branding hallmark), EBITDA margin 18.6%, operating ~15.3%, net ~22% GAAP TTM (flattered by the discontinued-ops gain; clean continuing net margin ~11–12%). Gross margin is the durable tell — pricing power holds.
Earnings: FY25 net income $789M, EPS $2.94 (diluted $2.93) — essentially flat vs FY24 ($788M / $2.94). Earnings are not growing fast.
Cash flow: FY25 operating CF $962M, capex −$222M, FCF ~$740M (FCF yield ~5.2%). FCF comfortably covers the ~$483M dividend (payout ~31% of earnings, ~65% of FCF).
Balance sheet: total debt $4.0B, net debt $3.9B, net-debt/EBITDA ~3.4× — the single biggest quality knock. Deleveraging is underway (net debt fell from $4.4B FY23 → $3.9B FY25) but the balance sheet is not a fortress. Goodwill + intangibles are $8.6B (65% of assets) — legacy of the Cholula/FONA/RB Foods deals. Current ratio 0.78 (below 1, typical for a working-capital-efficient staple).
6. Valuation — priced in or room?
Important valuation caveat: FMP's headline TTM P/E of ~8.9× is distorted by the $886M one-time discontinued-ops gain in Q1 FY26 — ignore it. On clean, continuing earnings the picture is:
P/E: ~18× FY26E ($3.09) → ~16× FY27E ($3.30) → ~12× FY30E ($4.63E). A staple growing EPS ~9% at ~16× forward is reasonable but not cheap — roughly fair.
EV/EBITDA 13.8× and EV/Sales 2.6× — mid-range for premium packaged food; the branded-spice premium is justified by the 38% gross margin, but the 3.4× leverage means EV multiples matter more than equity multiples here.
Dividend: yield 3.5%, 39 consecutive years of raises (a Dividend Aristocrat) — the core of the total-return case.
PEG: forward ~1.3 (FMP) — fairly valued on growth-adjusted terms.
Street targets (context, not our anchor): consensus $61.40, high $72, low $52. Our $55 base-case FV is below consensus — we discount the Street's willingness to pay ~19× for ~5% top-line growth on a leveraged balance sheet in a downtrend. This is a fairly-valued, wait-for-a-better-entry name, not a value buy.
7. Technicals (computed from EOD price history)
Trend:down. $53.45 sits above the 50-DMA ($48.4) but below the 200-DMA ($60.0) — a rally within a broader downtrend; the 50 is below the 200 (death-cross posture).
Location:−30% off the 52-week high ($76.56), +17% off the 52-week low ($45.60), and a punishing −49% max drawdown from peak. This is a broken chart that has not yet repaired.
Momentum: RSI(14) 64 — firm on the recent bounce, not overbought, but occurring below the 200-DMA (a lower-quality signal than an uptrend RSI).
Relative strength (the tell): MKC −30.7% 12-mo vs SPY +20.6% and QQQ +30.3% — massive underperformance. Even 3-mo (+10.5%) lags QQQ (+22.0%). This is a serial laggard, not a leader.
Read: technicals do not confirm a buy. A base above the 200-DMA (~$60) would be the constructive signal to watch for; until then the trend argues patience — consistent with the Watch verdict.
8. Moat & competitive position
McCormick's moat is real and old-fashioned: (1) brand + shelf dominance — the #1 branded spice player in the US with iconic marks (McCormick, French's, Frank's RedHot, Old Bay); (2) scale & distribution — the deepest spice supply chain globally, hard to replicate; (3) switching-cost stickiness in Flavor Solutions — its custom formulations are embedded in big food manufacturers' recipes. The durable 38% gross margin and 26% ROE are the moat made visible. The threats are unglamorous but real: private-label / store-brand spices (the perennial staple risk, sharper when consumers trade down), soft global volumes, and China weakness.
Peer set (market cap): J.M. Smucker $12.4B (closest branded-food comp), Hormel $13.8B, Campbell Soup $7.0B, Tyson Foods $21.0B, Bunge $20.7B, Lamb Weston $6.3B, Performance Food Group $17.8B, US Foods $23.0B, Coca-Cola FEMSA $22.6B. Within packaged food, MKC earns the highest gross margin and ROE in this group — the quality is not in question; the growth and leverage are.
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly for a mature staple — dividend first (~$483M/yr, 39-year raise streak, ~31% payout), modest buybacks (~$35M FY25), light capex (~3% of sales), and steady deleveraging (net debt $4.4B FY23 → $3.9B FY25). CEO Brendan Foley (Chairman, President & CEO). Appropriate priorities, but they confirm this is a return-of-capital story, not a growth-reinvestment one.
Insider activity: the sampled window (through 2026-07-01) shows routine grant/award and phantom-stock activity (CEO Foley, CHRO Piper, several directors) — compensation mechanics, not conviction buying or alarming discretionary selling. Neutral signal.
Management's own guidance:not available. The SEC 8-K route (Item 2.02) returned no usable earnings-release guidance text for this pull ("exhibit too thin"), so we do not summarize management's forward outlook here rather than fabricate it. When a clean earnings release is captured, this section will carry management's own (half-weighted, self-interested) guidance.
10. Catalysts & what to watch
Next earnings: 2026-10-06 (Q3 FY26; Street EPS $0.75, revenue ~$1.98B). Key line: organic volume growth (has it turned positive and durable?) and gross margin trajectory.
Volume vs price: the multi-year question is whether McCormick can grow volume, not just price — the Q2 FY26 +16.7% YoY revenue print is encouraging but needs to persist.
Deleveraging: further reduction in net-debt/EBITDA below ~3.0× would meaningfully de-risk the equity.
China / Flavor Solutions: recovery in the soft APAC region and Flavor Solutions client wins are the two real growth legs.
Private-label pressure: watch for trade-down in a weak-consumer environment.
Thesis tripwires (what would change the call): a break and hold above the 200-DMA (~$60) on improving volumes would push toward a Buy — Tactical; conversely, negative organic volume plus stalled deleveraging would push toward Avoid.
11. Key risks
Leverage (structural): net-debt/EBITDA 3.4× on a slow-growth base is the primary risk — higher-for-longer rates raise refinancing cost and limit flexibility.
Slow / stalling growth: ~5% forward revenue CAGR with historically soft organic volume; if price-driven growth fades, the thesis weakens.
Private-label / trade-down: store-brand spices are the perennial staple threat, sharper in a pinched-consumer environment.
Downtrend / de-rating: the stock is below its 200-DMA and has underperformed the market by ~50 points over 12 months — momentum is against it.
Goodwill/intangibles (65% of assets): acquisition-heavy balance sheet raises impairment risk if brand economics deteriorate.
No expert coverage: the absence of any tracked-voice conviction means we have less independent corroboration than for a covered name — a genuine information gap, disclosed.
12. Verdict, position sizing & monitoring
Watch. McCormick is a legitimately high-quality, wide-moat, Dividend-Aristocrat spice franchise (38% gross margin, 26% ROE, ~$740M FCF, 39-year dividend-raise streak) — but three things keep it out of the Buy bucket today: (1) growth is slow and not accelerating (~5% revenue / ~9% EPS forward CAGR); (2) the balance sheet is leveraged at 3.4× net-debt/EBITDA; and (3) the stock is in a real downtrend (−31% 12-mo, below the 200-DMA) with our base-case fair value (~$55) roughly at the current price. There is no expert coverage in the Synthos KB, so this is a fundamentals/quant-only call — and the fundamentals say fine company, no urgency.
Sizing: if owned at all, an income/defensive satellite, ≤2% — for the 3.5% yield and low-beta ballast, not for growth. Better entries likely below ~$48 (toward the 50-DMA / prior support) or on a confirmed break back above the 200-DMA.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-10-06). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $53.45.
Single biggest risk: a leveraged, slow-growth staple caught between private-label share loss and higher-for-longer rates.
Provenance & disclosures
Traceability:0 KB claims for MKC — no expert coverage exists in the Synthos knowledge base, and this note states that plainly. The verdict is fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation); here there are simply no claims to cite.
Data as-of: fundamentals 2026-05-31 (Q2 FY26) · estimates & prices 2026-07-02/03. Forward figures are analyst consensus (FMP), labeled as estimates. The headline TTM P/E is distorted by a one-time discontinued-ops gain (Q1 FY26) — we use clean forward multiples throughout.
Management caveat: management's own forward guidance was not available via the SEC 8-K route for this pull; none is summarized rather than fabricated.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").